Vineet Laboratories Ltd
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
- Market Cap ₹ 57.5 Cr.
- Current Price ₹ 29.9
- High / Low ₹ 43.8 / 21.4
- Stock P/E
- Book Value ₹ 7.40
- Dividend Yield 0.00 %
- ROCE -28.0 %
- ROE -89.5 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 4.04 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -3.43%
- Promoter holding is low: 12.5%
- Company has a low return on equity of -21.7% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 0 | 243 | 191 | 212 | 151 | 75 | 55 | |
| 0 | 235 | 178 | 205 | 143 | 91 | 60 | |
| Operating Profit | -0 | 8 | 13 | 8 | 7 | -16 | -5 |
| OPM % | 3% | 7% | 4% | 5% | -22% | -9% | |
| 0 | 0 | 0 | 0 | 0 | 2 | 1 | |
| Interest | 0 | 3 | 2 | 3 | 5 | 4 | 5 |
| Depreciation | 0 | 2 | 2 | 2 | 3 | 2 | 3 |
| Profit before tax | -0 | 4 | 9 | 2 | 0 | -21 | -11 |
| Tax % | 0% | 56% | 29% | 38% | -183% | -3% | |
| -0 | 2 | 7 | 1 | 1 | -20 | -10 | |
| EPS in Rs | -0.11 | 0.93 | 3.46 | 0.65 | 0.54 | -10.52 | -5.28 |
| Dividend Payout % | 0% | 0% | 14% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -27% |
| TTM: | -44% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -31% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -11% |
| 1 Year: | -5% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -9% |
| 3 Years: | -22% |
| Last Year: | -89% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.41 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | -0 | 17 | 24 | 24 | 26 | 5 | 5 |
| 0 | 12 | 27 | 31 | 44 | 40 | 43 | |
| 0 | 70 | 74 | 51 | 38 | 40 | 34 | |
| Total Liabilities | 0 | 109 | 133 | 116 | 117 | 95 | 91 |
| 0 | 20 | 21 | 27 | 27 | 25 | 24 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 89 | 112 | 89 | 90 | 69 | 66 | |
| Total Assets | 0 | 109 | 133 | 116 | 117 | 95 | 91 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 0 | 27 | 8 | -10 | -7 | 11 | |
| 0 | -8 | -4 | -7 | -2 | -3 | |
| 0 | 19 | 12 | 0 | 8 | -8 | |
| Net Cash Flow | 0 | 38 | 16 | -16 | -0 | 0 |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 64 | 69 | 60 | 77 | 64 | |
| Inventory Days | 73 | 109 | 98 | 158 | 260 | |
| Days Payable | 114 | 161 | 74 | 103 | 175 | |
| Cash Conversion Cycle | 23 | 17 | 84 | 131 | 150 | |
| Working Capital Days | 14 | -19 | 21 | 28 | -37 | |
| ROCE % | 34% | 23% | 9% | 7% | -28% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Feb - Copies of Un-audited standalone financial results of the company for the Third quarter and Nine months ended on December 31, 2025 published in following Newspapers …
- Unaudited Standalone Financial Results Along With The Limited Review Report For The Period Ended On December 31, 2025 14 Feb
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday, February 14, 2026 As Required Under Regulation 30 Of SEBI (LODR) Regulations, 2015
14 Feb - Board approved Q3 and nine-month unaudited results to Dec 31, 2025; limited review unqualified; vendor payments ratified.
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 11 Feb
-
Board Meeting Intimation for Considering And Approving The Unaudited Standalone Financial Results Of The Company For The Third Quarter Ended On December 31, 2025 Along With The Limited Review Report
10 Feb - Board meeting Feb 14, 2026 to approve unaudited standalone results for quarter ended Dec 31, 2025.
Product Profile:
a) API Intermediates:[1] Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine
b) Fine Chemicals and Reagents:[2] IPTG, PNPP, X-Gal, ATCA, Butyl Lithium, Furaldehyde, Butylnitrite, Aminouracil, etc.